{
  "quoteSummary": {
    "result": [
      {
        "defaultKeyStatistics": {
          "maxAge": 1,
          "priceHint": {
            "raw": 2,
            "fmt": "2",
            "longFmt": "2"
          },
          "enterpriseValue": {
            "raw": 471261478912,
            "fmt": "471.26B",
            "longFmt": "471,261,478,912"
          },
          "forwardPE": {},
          "profitMargins": {
            "raw": 0.07927,
            "fmt": "7.93%"
          },
          "floatShares": {
            "raw": 504804963,
            "fmt": "504.8M",
            "longFmt": "504,804,963"
          },
          "sharesOutstanding": {
            "raw": 804510016,
            "fmt": "804.51M",
            "longFmt": "804,510,016"
          },
          "sharesShort": {},
          "sharesShortPriorMonth": {},
          "sharesShortPreviousMonthDate": {},
          "dateShortInterest": {},
          "sharesPercentSharesOut": {},
          "heldPercentInsiders": {},
          "heldPercentInstitutions": {},
          "shortRatio": {},
          "shortPercentOfFloat": {},
          "beta": {
            "raw": -0.340977,
            "fmt": "-0.34"
          },
          "morningStarOverallRating": {},
          "morningStarRiskRating": {},
          "category": null,
          "bookValue": {
            "raw": 165.2,
            "fmt": "165.20"
          },
          "priceToBook": {
            "raw": 3.9987893,
            "fmt": "4.00"
          },
          "annualReportExpenseRatio": {},
          "ytdReturn": {},
          "beta3Year": {},
          "totalAssets": {},
          "yield": {},
          "fundFamily": null,
          "fundInceptionDate": {},
          "legalType": null,
          "threeYearAverageReturn": {},
          "fiveYearAverageReturn": {},
          "priceToSalesTrailing12Months": {},
          "lastFiscalYearEnd": {
            "raw": 1490918400,
            "fmt": "2017-03-31"
          },
          "nextFiscalYearEnd": {
            "raw": 1553990400,
            "fmt": "2019-03-31"
          },
          "mostRecentQuarter": {
            "raw": 1514678400,
            "fmt": "2017-12-31"
          },
          "earningsQuarterlyGrowth": {
            "raw": 0.069,
            "fmt": "6.90%"
          },
          "revenueQuarterlyGrowth": {},
          "netIncomeToCommon": {
            "raw": 11701300224,
            "fmt": "11.7B",
            "longFmt": "11,701,300,224"
          },
          "trailingEps": {
            "raw": 14.516,
            "fmt": "14.52"
          },
          "forwardEps": {},
          "pegRatio": {},
          "lastSplitFactor": "5/2",
          "lastSplitDate": {
            "raw": 1145836800,
            "fmt": "2006-04-24"
          },
          "enterpriseToRevenue": {
            "raw": 3.192,
            "fmt": "3.19"
          },
          "enterpriseToEbitda": {
            "raw": 18.492,
            "fmt": "18.49"
          },
          "52WeekChange": {
            "raw": "Infinity",
            "fmt": "\u00e2\u02c6\u017e%"
          },
          "SandP52WeekChange": {
            "raw": 0.17201865,
            "fmt": "17.20%"
          },
          "lastDividendValue": {},
          "lastCapGain": {},
          "annualHoldingsTurnover": {}
        },
        "summaryProfile": {
          "address1": "Cipla House",
          "address2": "Peninsula Business Park Ganpatrao Kadam Marg Lower Parel",
          "city": "Mumbai",
          "zip": "400013",
          "country": "India",
          "phone": "91 22 2482 6000",
          "fax": "91 22 2482 6120",
          "website": "http://www.cipla.com",
          "industry": "Drug Manufacturers - Major",
          "sector": "Healthcare",
          "longBusinessSummary": "Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women's health, cardiovascular, children's health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including equine and companion care, livestock, poultry, swine, and aqua products. In addition, it offers inhalation therapy devices comprising metered-dose inhalers, dry powder inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, North America, Australia, New Zealand, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.",
          "companyOfficers": [],
          "maxAge": 86400
        },
        "financialData": {
          "maxAge": 86400,
          "currentPrice": {
            "raw": 660.6,
            "fmt": "660.60"
          },
          "targetHighPrice": {},
          "targetLowPrice": {},
          "targetMeanPrice": {},
          "targetMedianPrice": {},
          "recommendationMean": {},
          "recommendationKey": "none",
          "numberOfAnalystOpinions": {},
          "totalCash": {
            "raw": 26545199104,
            "fmt": "26.55B",
            "longFmt": "26,545,199,104"
          },
          "totalCashPerShare": {
            "raw": 32.978,
            "fmt": "32.98"
          },
          "ebitda": {
            "raw": 25484075008,
            "fmt": "25.48B",
            "longFmt": "25,484,075,008"
          },
          "totalDebt": {
            "raw": 47842598912,
            "fmt": "47.84B",
            "longFmt": "47,842,598,912"
          },
          "quickRatio": {},
          "currentRatio": {},
          "totalRevenue": {
            "raw": 147617497088,
            "fmt": "147.62B",
            "longFmt": "147,617,497,088"
          },
          "debtToEquity": {
            "raw": 34.976,
            "fmt": "34.98"
          },
          "revenuePerShare": {
            "raw": 183.454,
            "fmt": "183.45"
          },
          "returnOnAssets": {},
          "returnOnEquity": {},
          "grossProfits": {
            "raw": 90680200000,
            "fmt": "90.68B",
            "longFmt": "90,680,200,000"
          },
          "freeCashflow": {},
          "operatingCashflow": {},
          "earningsGrowth": {
            "raw": 0.069,
            "fmt": "6.90%"
          },
          "revenueGrowth": {
            "raw": 0.073,
            "fmt": "7.30%"
          },
          "grossMargins": {
            "raw": 0.63912,
            "fmt": "63.91%"
          },
          "ebitdaMargins": {
            "raw": 0.17264,
            "fmt": "17.26%"
          },
          "operatingMargins": {
            "raw": 0.110010006,
            "fmt": "11.00%"
          },
          "profitMargins": {
            "raw": 0.07927,
            "fmt": "7.93%"
          },
          "financialCurrency": "INR"
        }
      }
    ],
    "error": null
  }
}